Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients

Melek Simsek, Berrie Meijer, Dewkoemar Ramsoekh, Gerd Bouma, Egbert-Jan van der Wouden, Bert den Hartog, Annemarie C de Vries, Frank Hoentjen, Gerard Dijkstra, Sybrand Y de Boer, Jeroen M Jansen, Andrea E van der Meulen, Ruud Beukers, Menno A Brink, Toos Steinhauser, Bas Oldenburg, Lennard P Gilissen, Ton H Naber, Marc A Verhagen, Nanne K H de BoerChris J J Mulder,

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD). 1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown. 2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course.

Original languageEnglish
Pages (from-to)568-570
Number of pages3
JournalClinical Gastroenterology and Hepatology
Volume17
Issue number3
Early online date2018
DOIs
Publication statusPublished - Feb 2019

Fingerprint

Dive into the research topics of 'Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients'. Together they form a unique fingerprint.

Cite this